Changes in tumor size by RECIST correlate with survival

June 13, 2012
Changes in tumor size by RECIST correlate with survival
RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

(HealthDay) -- RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival (OS) but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

Rajul K. Jain, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues studied the correlation between OS and response, as quantified by RECIST, in 570 participants of 24 phase I oncology trials conducted between October 2004 and May 2009.

The researchers found that 468 of the participants had quantifiable changes in tumor size. Change in tumor size during exposure to anticancer agents, as quantified by RECIST, correlated well with OS in a near-linear fashion without clear inflection points. Residual analyses were used to confirm the association.

"RECIST quantification of response correlates with survival, validating RECIST's use in phase I trials. However, the lack of apparent boundary values in the relationship between change in and OS demonstrates the arbitrary nature of the complete response/partial response/stable disease/ categories and questions emphasis placed on this categorization scheme," the authors write. "Describing tumor responses as a continuous variable may be more informative than reporting categoric responses when evaluating novel ."

One author disclosed a financial tie to Amgen.

Explore further: Pancreatectomy OK without downstaging from therapy

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pancreatectomy OK without downstaging from therapy

May 25, 2012
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May ...

Chemotherapy's effect on overall survival seems to increase based on tumor size

May 15, 2012
The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node ...

High survival with surgery in low-risk neuroblastoma

April 25, 2012
(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.